Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Tzogani, K"" wg kryterium: Autor


Wyświetlanie 1-2 z 2
Tytuł :
European Medicines Agency review of midostaurin (Rydapt) for the treatment of adult patients with acute myeloid leukaemia and systemic mastocytosis.
Autorzy :
Tzogani K; European Medicines Agency, Amsterdam, The Netherlands Kyriaki.Tzogani@ema.europa.eu.
Yu Y; Medicines Evaluation Board, Utrecht, The Netherlands.
Meulendijks D; Medicines Evaluation Board, Utrecht, The Netherlands.
Herberts C; Medicines Evaluation Board, Utrecht, The Netherlands.
Hennik P; Medicines Evaluation Board, Utrecht, The Netherlands.
Verheijen R; Medicines Evaluation Board, Utrecht, The Netherlands.
Wangen T; Statens legemiddelverk, Oslo, Norway.
Dahlseng Håkonsen G; Statens legemiddelverk, Oslo, Norway.
Kaasboll T; Statens legemiddelverk, Oslo, Norway.
Dalhus M; Statens legemiddelverk, Oslo, Norway.
Bolstad B; Statens legemiddelverk, Oslo, Norway.
Salmonson T; European Medicines Agency, Amsterdam, The Netherlands.
Gisselbrecht C; Institut d hématologie Hôpital Saint Louis Paris Diderot université, Hospital Saint-Louis, Paris, France.
Pignatti F; European Medicines Agency, Amsterdam, The Netherlands.
Pokaż więcej
Źródło :
ESMO open [ESMO Open] 2019 Nov; Vol. 4 (6).
Typ publikacji :
Journal Article; Review
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Leukemia, Myeloid, Acute/*drug therapy
Mastocytosis, Systemic/*drug therapy
Protein Kinase Inhibitors/*adverse effects
Staurosporine/*analogs & derivatives
Administration, Oral ; Adult ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Diarrhea/chemically induced ; Diarrhea/epidemiology ; Disease-Free Survival ; Dose-Response Relationship, Drug ; Drug Administration Schedule ; Drug Approval ; Edema/chemically induced ; Edema/epidemiology ; European Union ; Fatigue/chemically induced ; Fatigue/epidemiology ; Female ; Humans ; Leukemia, Myeloid, Acute/genetics ; Leukemia, Myeloid, Acute/mortality ; Male ; Mastocytosis, Systemic/genetics ; Mastocytosis, Systemic/mortality ; Middle Aged ; Nausea/chemically induced ; Nausea/epidemiology ; Protein Kinase Inhibitors/administration & dosage ; Randomized Controlled Trials as Topic ; Risk Assessment ; Staurosporine/administration & dosage ; Staurosporine/adverse effects ; Vomiting/chemically induced ; Vomiting/epidemiology ; fms-Like Tyrosine Kinase 3/antagonists & inhibitors ; fms-Like Tyrosine Kinase 3/genetics
Czasopismo naukowe
Tytuł :
The European Medicines Agency Review of Carfilzomib for the Treatment of Adult Patients with Multiple Myeloma Who Have Received at Least One Prior Therapy.
Autorzy :
Tzogani K; European Medicines Agency, London, United Kingdom kyriaki.tzogani@ema.europa.eu.
Camarero Jiménez J; European Medicines Agency, London, United Kingdom.; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
Garcia I; European Medicines Agency, London, United Kingdom.; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
Sancho-López A; European Medicines Agency, London, United Kingdom.; Agencia Española de Medicamentos y Productos Sanitarios, Madrid, Spain.
Martin M; European Medicines Agency, London, United Kingdom.; French National Agency for Medicines and Health Products Safety, Saint-Denis Cedex, France.
Moreau A; European Medicines Agency, London, United Kingdom.; French National Agency for Medicines and Health Products Safety, Saint-Denis Cedex, France.
Demolis P; European Medicines Agency, London, United Kingdom.; French National Agency for Medicines and Health Products Safety, Saint-Denis Cedex, France.
Salmonson T; European Medicines Agency, London, United Kingdom.; Läkemedelsverket, Medicinal Products Agency, Uppsala, Sweden.
Bergh J; European Medicines Agency, London, United Kingdom.; Karolinska Institutet, Stockholm, Sweden.
Laane E; European Medicines Agency, London, United Kingdom.; North Estonia Regional Hospital, Tallinn, Estonia.
Ludwig H; European Medicines Agency, London, United Kingdom.; Wilhelminen Cancer Research Institute, Vienna, Austria.
Gisselbrecht C; European Medicines Agency, London, United Kingdom.; Hospital Saint Louis, Paris, France.
Pignatti F; European Medicines Agency, London, United Kingdom.
Pokaż więcej
Źródło :
The oncologist [Oncologist] 2017 Nov; Vol. 22 (11), pp. 1339-1346. Date of Electronic Publication: 2017 Sep 21.
Typ publikacji :
Clinical Trial, Phase III; Journal Article; Randomized Controlled Trial
MeSH Terms :
Antineoplastic Combined Chemotherapy Protocols/*administration & dosage
Multiple Myeloma/*drug therapy
Neoplasm Recurrence, Local/*drug therapy
Oligopeptides/*administration & dosage
Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Dexamethasone/administration & dosage ; Dexamethasone/adverse effects ; Disease Progression ; Disease-Free Survival ; Drug-Related Side Effects and Adverse Reactions/classification ; Drug-Related Side Effects and Adverse Reactions/pathology ; Europe/epidemiology ; Female ; Humans ; Lenalidomide ; Male ; Middle Aged ; Multiple Myeloma/epidemiology ; Multiple Myeloma/pathology ; Neoplasm Recurrence, Local/pathology ; Oligopeptides/adverse effects ; Thalidomide/administration & dosage ; Thalidomide/adverse effects ; Thalidomide/analogs & derivatives
Czasopismo naukowe
    Wyświetlanie 1-2 z 2

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies